Pacritinib

From WikiMD.org
Jump to navigation Jump to search

Pacritinib

Pacritinib (pronounced puh-kri-ti-nib) is a Janus kinase inhibitor used in the treatment of myelofibrosis, a rare type of bone marrow disease.

Etymology

The name "Pacritinib" is derived from the pharmaceutical company that developed it, Pacira Pharmaceuticals, and the class of drugs it belongs to, known as tyrosine kinase inhibitors.

Usage

Pacritinib is used to treat patients with myelofibrosis, including those with low platelet counts. It works by blocking certain proteins that can affect the growth of cancer cells.

Related Terms

  • Janus kinase inhibitor: A type of drug that blocks the action of Janus kinases, proteins involved in the body's immune response and the growth of cancer cells.
  • Myelofibrosis: A serious bone marrow disorder that disrupts the body's normal production of blood cells.
  • Bone marrow: The spongy tissue inside some of your bones, such as your hip and thigh bones, which contains immature cells, called stem cells.
  • Tyrosine kinase inhibitors: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can stimulate the growth of cancer cells.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski